SHANGHAI, Oct.14, 2024--Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced that the launch conference for“An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Non-Small Cell Lung Cancer”was successfully held in both online and offline at the leading unit, Shanghai Chest Hospital. 

Professor Lu Shun and Director Li Ziming from the Oncology Department of Shanghai Chest Hospital, Director Chu Tianqing from the drug clinical trial institution, and the relevant clinical research team, as well as Juncell Vice President Lin Shuwei and the clinical medical team, participated in the conference. 

This is the first registered clinical trial in China specifically targeting lung cancer with TIL cell therapy, and it also marks another significant advancement for Jun Sai Biotech in expanding the indications of TIL therapy for solid tumors. 

This is the first registered clinical trial in China specifically for lung cancer with TIL therapy, and it also marks another significant advancement for Juncell Therapeutics in expanding the indications of solid tumors. 

About GC101 

GC101 is an autologous natural TIL TIL therapy developed leveraging Juncell Therapeutics' proprietary DeepTIL® cell expansion platform. DeepTIL® enables TILs to be potent enough that no IL-2 combination will be required after infusion, and the intensity of pretreatment could be lower. 

As the first TIL therapy which only needs low-intensity pre-treatment and no IL-2 injection in the world, GC101 has been validated for its clinical efficacy and safety which greatly improves the safety and accessibility of TIL therapy. 

About MIZAR-005 

MIZAR-005 is an open-label, single-arm phase 1b clinical trial, aimed to investigate the safety and efficacy of GC203 in the Non-small-cell lung cancer (NSCLC) patients. 

About Juncell Therapeutics 

Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible TIL cell therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible." Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in the treatment of ten types of heavily pretreated advanced solid tumors, including lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, ovarian cancer, endometrial cancer, cervical cancer, bile duct cancer and melanoma. 7 of these late-stage tumor patients have achieved CR, and the longest tumor-free survival time is over 3 years.